Brimonidine
- Generic Name
- Brimonidine
- Brand Names
- Alphagan, Combigan, Lumify, Mirvaso, Onreltea, Qoliana, Simbrinza
- Drug Type
- Small Molecule
- Chemical Formula
- C11H10BrN5
- CAS Number
- 59803-98-4
- Unique Ingredient Identifier
- E6GNX3HHTE
- Background
Brimonidine is an alpha-adrenergic agonist and 2-imidazoline derivative that was first introduced in 1996. It is considered to be a third generation alpha-2 aadrenergic receptor agonist, since it displays preferential binding at alpha-2 adrenoceptors over alpha-1 receptors. Brimonidine displays a higher selectivity toward the alpha-2 adrenergic receptors tha...
- Indication
Opthalmic
Indicated for lowering intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension as monotherapy or combination product with brinzolamide.
Topical
Indicated for the treatment of persistent (non-transient) facial erythema of rosacea in adults 18 years of age or older.
- Associated Conditions
- Increased Intra Ocular Pressure (IOP), Ocular Hypertension, Facial erythema
- Associated Therapies
- -
Effect of Netarsudil vs Brimonidine in NTG Patients on Latanoprost
- First Posted Date
- 2024-06-10
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Westlake Eye Specialists
- Target Recruit Count
- 100
- Registration Number
- NCT06449352
- Locations
- 🇺🇸
Westlake Eye Specialists - New Braunfels Office, New Braunfels, Texas, United States
🇺🇸Westlake Eye Specialists - Kyle Office, Kyle, Texas, United States
🇺🇸Westlake Eye Specialists - Austin Office, Austin, Texas, United States
Phase 3 Evaluation of the Safety and Efficacy of LNZ101 for the Treatment of Presbyopia
- Conditions
- Interventions
- First Posted Date
- 2022-12-19
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- LENZ Therapeutics, Inc
- Target Recruit Count
- 469
- Registration Number
- NCT05656027
- Locations
- 🇺🇸
Site #121, Mesa, Arizona, United States
🇺🇸Site #104, Fargo, North Dakota, United States
🇺🇸Site #122, Phoenix, Arizona, United States
Safety and Efficacy Study BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic or Pseudophakic Presbyopia
- Conditions
- Interventions
- First Posted Date
- 2022-03-08
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Visus Therapeutics
- Target Recruit Count
- 182
- Registration Number
- NCT05270863
- Locations
- 🇺🇸
Visus Therapeutics Investigative Site, Ogden, Utah, United States
Comparison of a Compound With Pilocarpine and Brimonidine to Improve Near Vision in Healthy Presbyopic Patients
- First Posted Date
- 2021-08-11
- Last Posted Date
- 2021-08-19
- Lead Sponsor
- Optall Vision
- Target Recruit Count
- 11
- Registration Number
- NCT05001243
- Locations
- 🇲🇽
Optall Vision, Mexico City, Mexico
Choroidal Thickness and Its Correlations With Ocular Parameters in Primary Open-angle Glaucoma
- Conditions
- Interventions
- First Posted Date
- 2019-05-29
- Last Posted Date
- 2019-05-29
- Lead Sponsor
- Afyon Kocatepe University Hospital
- Target Recruit Count
- 96
- Registration Number
- NCT03966560
The Effect of Brimonidine
- Conditions
- Interventions
- First Posted Date
- 2019-05-22
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 13
- Registration Number
- NCT03959176
- Locations
- 🇺🇸
Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States
Study of Brimonidine Tartrate Nanoemulsion Eye Drop Solution in the Treatment of Dry Eye Disease (DED)
- First Posted Date
- 2018-12-24
- Last Posted Date
- 2022-07-18
- Lead Sponsor
- Ocugen
- Target Recruit Count
- 252
- Registration Number
- NCT03785340
- Locations
- 🇺🇸
Ophthalmology Associates, Saint Louis, Missouri, United States
🇺🇸Martel Medical Eye Group, Rancho Cordova, California, United States
🇺🇸Rand Eye Institute, Pompano Beach, Florida, United States
Pupil Dilation for Treatment of IFIS
- Conditions
- Interventions
- First Posted Date
- 2018-11-30
- Last Posted Date
- 2022-04-20
- Lead Sponsor
- Denver Health and Hospital Authority
- Target Recruit Count
- 13
- Registration Number
- NCT03760185
- Locations
- 🇺🇸
Denver Health, Denver, Colorado, United States
Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease
- First Posted Date
- 2018-07-19
- Last Posted Date
- 2022-07-06
- Lead Sponsor
- Ocugen
- Target Recruit Count
- 59
- Registration Number
- NCT03591874
- Locations
- 🇺🇸
Emory Eye Center, Atlanta, Georgia, United States
🇺🇸Ohio State University, Columbus, Ohio, United States
🇺🇸University of Penn Scheie Eye Institute,, Philadelphia, Pennsylvania, United States
Treatment of Asian Flushing Syndrome With Topical Alpha Agonists
- Conditions
- Interventions
- First Posted Date
- 2018-04-13
- Last Posted Date
- 2020-05-04
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 20
- Registration Number
- NCT03497442
- Locations
- 🇺🇸
UC, San Francisco, San Francisco, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.